11750 Sorrento Valley Road
Suite 200
San Diego, CA 92121
United States
979-446-0027
https://www.ibioinc.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 26
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Martin B. Brenner D.V.M., Ph.D. | CEO, Chief Scientific Officer & Director | 577.31k | N/A | 1970 |
Mr. Felipe Duran | Chief Financial Officer | 1.07M | N/A | 1979 |
Mr. Marc Banjak J.D. | Chief Legal Officer | N/A | N/A | N/A |
Ms. Kristi Sarno | Senior VP of Business Development | N/A | N/A | N/A |
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company's vaccines and therapeutics in preclinical development. Its EngageTx technology targets bi-specific molecules and its pre-clinical data demonstrates the ability to generate multiple hits creating sequence diversity and promoting Human-Cyno cross reactivity while mitigating cytokine release. The company also has ShieldTx, a patent-pending antibody masking technology designed to enable specific targeted antibody delivery to diseased tissue without harming healthy tissue. The company was incorporated in 2008 and is headquartered in San Diego, California.
iBio, Inc.’s ISS governance QualityScore as of 18 September 2024 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 4; Compensation: 9.